• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Biochem Biophys Res Commun . Development of human single-domain antibodies against influenza based on NA-targeting IgG

tetano

Editor, Senior Moderator
Biochem Biophys Res Commun


. 2026 Jan 2:798:153238.
doi: 10.1016/j.bbrc.2026.153238. Online ahead of print. Development of human single-domain antibodies against influenza based on NA-targeting IgG

Ailing Huang[SUP] 1 [/SUP], Cheng Li[SUP] 2 [/SUP], Hui Wu[SUP] 2 [/SUP], Wenli Sun[SUP] 2 [/SUP], Shanshan Huo[SUP] 1 [/SUP], Juan Wang[SUP] 1 [/SUP], Yanling Wu[SUP] 3 [/SUP], Tianlei Ying[SUP] 4 [/SUP], Fei Yu[SUP] 5 [/SUP]



Affiliations
Abstract

The neuraminidase (NA) of influenza A virus (IAV) is an important antiviral target. However, antibodies require precise recognition of the catalytic pocket to exert antiviral effects, making them difficult to obtain through conventional screening. Traditional IgG antibodies also suffer from poor aerosolization efficiency, limiting their effectiveness for respiratory delivery. Human single-domain antibodies (sdAbs) with only the variable domain of the heavy chain (VH) show great potential in combating respiratory viral infections because of their small molecular weight and superior inhalable properties; however, sdAbs often lose stability or binding activity when isolated directly from parental IgG antibodies. To overcome these barriers and accelerate the acquisition of fully human sdAbs targeting the NA active pocket, we extracted the VH domain from broadly neutralizing anti-NA IgG and applied scaffold grafting followed by affinity recovery. Ultimately, we obtained two fully human sdAbs with favorable physicochemical properties that inhibited H5N8 NA enzymatic activity, with IC[SUB]50[/SUB] values of 0.82 and 0.59 μg mL[SUP]-1[/SUP]. This work enabled the originally insoluble VH fragment of IgG to be expressed in a stable and soluble form and restored its NA-binding activity from undetectable levels to the nanomolar range, providing insights into engineering fully human sdAbs capable of targeting structurally constrained viral enzymes and suitable for inhalable influenza therapeutics.

Keywords: Affinity recovery; Antibody mutant library; Human single-domain antibodies; Influenza A virus; Influenza virus neuraminidase; Phage display.

 
Back
Top